GLP-1s reshape cannabis demand
- Reporting indicates GLP-1 weight-loss drugs are changing U.S. cannabis retail sales and store strategies. - Retailers report reduced appetite and shifting purchase patterns among customers using GLP-1 treatments. - The shift is a concrete example of how a successful product in one category can materially alter adjacent consumer markets. (prismnews.com)
Cannabis dispensaries in the U.S. are changing what they stock and recommend as more customers use GLP-1 weight-loss drugs. (money.usnews.com) Reuters reported on April 20 that industry executives and researchers say the shift is showing up across a U.S. cannabis market they sized at about $40 billion. At Stoops NYC in Manhattan, staff said they are steering some GLP-1 users toward lower-dose edibles, vapes and tinctures instead of heavier edible use. (money.usnews.com) The basic overlap is simple: GLP-1 drugs such as Ozempic, Wegovy and Zepbound reduce appetite and slow digestion. That can blunt the “munchies” effect cannabis sellers have long relied on and can also make edible timing less predictable. (pmc.ncbi.nlm.nih.gov, money.usnews.com) The customer base is large enough for retailers to pay attention. KFF said in a poll published November 14, 2025, that 12% of U.S. adults were currently taking a GLP-1 drug, up from 18 months earlier. (kff.org) Other consumer industries are already adjusting to the same appetite shift. CNBC reported in March that restaurants and food companies were rolling out smaller portions and higher-protein options as GLP-1 use spread, with KPMG estimating users consume 21% fewer calories and spend nearly a third less on groceries on average. (cnbc.com, kpmg.com) Cannabis sellers say the change is not just about eating less. Reuters said some users are moving toward more targeted use for sleep or stress, and some appear to be substituting cannabis for alcohol rather than using it for appetite-driven occasions. (money.usnews.com) Questions from consumers are shifting too. Reuters reported that Realm of Caring, a cannabis education nonprofit, has seen hotline questions since 2024 such as “THC for weight loss,” “weed strains that suppress appetite,” and “edibles that don’t make you hungry.” (srnnews.com) Researchers are now testing whether the same drugs changing retail demand could also affect heavy cannabis use. A National Institute on Drug Abuse-backed Phase 2 trial listed on ClinicalTrials.gov plans to enroll 100 people with moderate to severe cannabis use disorder to test tirzepatide against placebo over 24 weeks. (clinicaltrials.gov) Earlier observational research has pointed in the same direction, with a 2024 study in Molecular Psychiatry finding semaglutide was associated with lower incidence and relapse of cannabis use disorder in electronic health records. The authors described that result as retrospective, not proof of cause and effect. (nature.com) For dispensaries, the immediate adjustment is practical: smaller doses, different formats and fewer assumptions that cannabis still means stronger cravings and bigger snack sales. (money.usnews.com)
